These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma.
    Author: Yodono H, Matsuo K, Shinohara A.
    Journal: Anticancer Drugs; 2011 Mar; 22(3):277-82. PubMed ID: 21360850.
    Abstract:
    Transcatheter arterial chemoembolization (TACE) is widely used to treat unresectable hepatocellular carcinoma (HCC). Recently, a fine-powder formulation of cisplatin (DDP-H) was developed in Japan. We aimed to compare clinical outcomes after TACE using epirubicin or DDP-H in patients with HCC. We evaluated 202 patients who were treated with TACE alone, using either epirubicin-lipiodol emulsion or DDP-H-lipiodol suspension. Of these, epirubicin and DDP-H treatment groups comprised 106 and 96 patients, respectively. The median follow-up time was 32 months (range: 1-45 months). The progression free survival rate in the DDP-H–lipiodol group was significantly higher than in the epirubicin-lipiodol group (log-rank test, P =0.0164). Moreover, the DDP-H–lipiodol group showed significantly better overall survival than the epirubicin-lipiodol group (log-rank test: P =0.0052). The overall survival rate at 1, 2, and 3 years was 88.5, 71.8 and 62.4%, respectively, for the DDP-H-lipiodol group and 83.0, 57.9 and 36.5%, respectively, in the epirubicin-lipiodol group. In a multivariate analysis, the independent factors affecting overall survival were drug (epirubicin vs. DDP-H; hazard ratio 0.44, P= 0.0001), clinical stage (I/II vs. III/IV; hazard ratio 1.93, P = 0.0026), and Child-Pugh score (A vs. B/C; hazard ratio 3.15, P < 0.0001). TACE using a gelatin sponge and lipiodol with DDP-H showed better progression-free survival and overall survival rates than TACE with the epirubicin-lipiodol emulsion in patients with HCC. The improvement of overall survival in patients with HCC receiving this treatment warrants further investigation as a randomized control trial.
    [Abstract] [Full Text] [Related] [New Search]